AAV Vector Titer Determination
Determination of adeno-associated virus vector titer by digital PCR with MiQuant® AAV.
- Fast and easy workflow
- Quantitation independent of AAV serotype
- TruTiter™ technology allows highly accurate results
- No DNA extraction required
- Designed for QIAcuity platform
- In-Process Control and Release Testing
- Quantiation without standard curve or further calculations
- Lyophilized kit components simplify logistics and storage
Gene therapy represents one of the most ground-breaking advancements in modern medicine that has rapidly evolved over the last years leading to improved methods of applications. Adeno-associated virus (AAV) vectors are among the most prominent viral vectors for in vivo gene therapy that target the healthy gene material to the correct location in the organism which enables the mutated gene to be exchanged by the healthy one.
Viral genome titer is a critical quality attribute in AAV characterization for safe and efficacious gene therapy products. Specificity of AAV vectors as well as the concentration of the vector titer must be determined throughout the production process and for final release testing.
The MiQuant® AAV kits have been developed for the determination of AAV vector titer. Different kit versions enable the specific detection of AAV genotype 2/6 (including genotype 1, 3 & 7) or genotype 5.
TruTiter™ technology - powered by Promega
A problem arising during AAV vector production is the occurrence of non-functional virus capsids that are either not filled with DNA or broken with leaking DNA. To avoid false positive results, the TruTiter™ reagent has been integrated into the MiQuant® AAV kits. By using this technology from Promega only DNA inside an intact capsid is amplified while free DNA and DNA of broken capsids is being masked and cannot be amplified. This allows highly accurate measurement of the AAV viral genome and eliminates the need for a DNase treatment step.
Application Areas
Determination of the AAV vector titer with the MiQuant® AAV kits is useful at different times. During the AAV vector production process, it can be used as an in-process control to evaluate the AAV titer. As part of the final QC release testing the AAV titer must be determined prior to administration to the patient. Besides these applications the MiQuant® AAV kits can also be used for determining the AAV titer in research and development.
Find more information on MiQuant® AAV in our flyer.
Download Flyer
Beta testers wanted!
Minerva Biolabs is looking for suitable testers for MiQuant® AAV. As a beta tester you will benefit from free test material and comprehensive technical support.
Please contact us at miquant@minerva-biolabs.com to get further information.